MarketCap
Facebook
X
Telegram
Verrica Pharmaceuticals Net Income | VRCA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Verrica Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.9 M | -76.6 M | -67 M | -24.5 M | -35.1 M | -42.7 M | -28.2 M | -20.6 M | -4.46 M | -1.91 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.91 M | -76.6 M | -31.9 M |
Quarterly Net Income Verrica Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.2 M | -9.68 M | -274 K | 204 K | -9.74 M | - | -22.9 M | -17.2 M | -20.3 M | - | -24.8 M | -11 M | -6.59 M | - | 83 K | -10.2 M | -8.47 M | - | -12.8 M | -11.8 M | -936 K | - | -10.5 M | -9.41 M | -9.82 M | -7.64 M | -6.09 M | -7 M | -7.48 M | -7.58 M | -5.91 M | -5.32 M | -1.85 M | -1.44 M | -1.36 M | -1.1 M | -570 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 204 K | -24.8 M | -8.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Galecto
GLTO
|
-210 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
154 K | - | 9357.83 % | $ 1.01 B |  USA |
 |
Graybug Vision
GRAY
|
-29.6 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
149 M | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-12.7 M | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
440 M | $ 10.83 | 10.69 % | $ 1.75 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
-8.28 M | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-12.5 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-104 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-110 M | - | - | $ 1.45 B |  Britain |
 |
KemPharm
KMPH
|
83.2 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-56 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-6.08 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-162 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-631 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-13 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-50.2 K | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
9.17 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-163 M | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
-209 M | $ 8.55 | -8.85 % | $ 593 M | USA |
|
BiomX
PHGE
|
-36.2 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
-41.7 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-22.4 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-23.8 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
-17 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
-19.9 M | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
-91 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
-130 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
-123 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
-12.5 M | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
-21.1 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
-16 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
-23.7 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
-1 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
-34.3 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
-12 M | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
5.18 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
31.7 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
-84.7 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-60.5 M | - | 7.29 % | $ 127 M | USA |
|
Windtree Therapeutics
WINT
|
-1.79 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
-66 M | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-79.5 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-71.2 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-8.38 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-28.9 M | - | - | $ 24.9 M | USA |